A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
Inclusion Criteria:
Exclusion Criteria:
Caba, Argentina
CABA, Argentina
Ciudad Autonoma de Buenos Aire, Argentina
Forestal Entre Ríos, 89862-000, Argentina
Saint-Peterburg, Russia
Kramatorsk, 84307, Ukraine
Kyiv, 02091, Ukraine
Poltava, 36039, Ukraine